Onco Actu du 13 juin 2016

	3.1 Tabac
Assessing Cancer Patients’ Tobacco Use: A New Tool Developed by the AACR and the National Cancer Institute [CANCER RESEARCH Catalyst] The basis for the NCI-AACR Task Force’s initiative to develop a standardized questionnaire is that a review of tobacco exposure surveys currently in use in cancer clinical trials revealed substantial variability in how clinical researchers were assessing previous and current tobacco use, making the findings of the different surveys difficult to compare.
	3.1.1 Tabac - e-cigs
Vaping teens more apt to move on to regular cigarettes: U.S. study [Reuters] The researchers based their findings on surveys conducted by USC involving about 300 high school students in southern California.
	5.3 Traitements - FDA, EMA,...
European ombudsman urges regulator to get tough on redacting study data [STAT] An EMA spokeswoman wrote us that the agency is “pleased” that the Ombudsman did not find any “maladministration” in its handling of the Humira redactions and maintained her findings support the agency approach to redacting commercially confidential information, or CCI.
	5.9.3 EHA
Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association [Seattle Genetics] Phase 1 Clinical Data Featured in Press Program and Oral Presentation Demonstrate 76 Percent Objective Response Rate, Including a 41 Percent Complete Remission Rate, in Newly Diagnosed AML Patients Treated with 33A Combination Therapy.
Daratumumab Significantly Extended Progression-Free Survival in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma [Johnson & Johnson] Data from Phase 3 MMY3003 (POLLUX) trial to be featured in the Presidential Symposium at the European Hematology Association (EHA) Annual Congress.
Allogeneic TCRα/CD38 Double Knockout T-cells bearing an anti-CD38 Chimeric Antigen Receptor (CAR): an improved immunotherapy for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and multiple myeloma (MM) [Cellectis] EHA Posters 2016.
	6. Lutte contre les cancers
Califf’s big idea: Build a database for research done before clinical trials [STAT] Speaking at an event here Thursday about the the challenges of reproducing major research results, Califf floated the idea of “something like a ClinicalTrials.gov for preclinical work.”
Four key ways to improve cancer patient care in Wales [Cancer Research UK] Yesterday we published our report, Where next for cancer services in Wales?, looking in detail at the challenges the nation faces. While there have been notable improvements in cancer care in Wales, with more people surviving than ever before, things are still a long way from where they should be.
The cancer drugs in your bathroom cabinet [The Guardian] Despite promising results like these, it could still be years before we know for sure if repurposed drugs work against cancer, and if so, how best to use them. But unfortunately, time is a luxury many cancer patients can’t afford. This has prompted some to take matters into their own hands.
	6.11 Patients
‘Becoming involved has given a new meaning to my life; it’s the best thing I’ve ever done’ – Terry’s story [Cancer Research UK] I’d like to think that, through being involved in research, I’ve used my cancer experience to benefit others and build a brand new life for myself. While I wouldn’t want cancer to find me again, I see it as one of the most profound and positive changes in my life.
I'm fighting cancer for the fourth time in four decades. Here we go again [The Globe and Mail] For the record, the treatment came as advertised, as close to a near-death experience as I ever hope to get before the real deal. What follows salvage? I consoled myself that at least I’d never be treated again. Only now comes another form of lymphoma, another course of chemo.
	6.5 Médecines alternatives
Stress, cancer and electromagnetic therapy – what does the evidence say? [Cancer Research UK] So despite various claims you may have read in the papers over the last few days, there’s no good evidence that stress causes cancer, nor that machines producing low-frequency electromagnetic pulses can help kill cancer cells in patients with the disease.
	6.6 Publications
Crap, Courtesy of a Major Scientific Publisher [In the Pipeline] Scientific Reports is a catch-all journal, for sure, the Nature Publishing Group’s answer to PLOS ONE. In theory, it’s not supposed to review for impact in any way, just for scientific accuracy. Once that’s established, the authors pay the fee and the paper gets published, and the whole thing is open-access. I don’t have a problem with that model. But it doesn’t work if you don’t review the damned papers.
More eLife authors are linking submissions to their ORCID iDs [eLife] The overall number of ORCID iDs nearly doubled over the course of 2015. At present there are more than 2.2 million researchers with ORCID iDs.
	6.7 DMP, Big Data & applis
Search engines can find pancreatic cancer? Times coverage needed a second opinion [HealthNewsReview] The Times coverage is notable for its utter lack of skepticism and its failure to challenge any of the concepts or claims made in the story. We don’t hear from any independent experts, even though the premise of the story is so extraordinary as to practically demand some outside scrutiny.
	6.8 Communication
How a student's death highlighted our reliance on companies for health advice [The Guardian] China’s equivalent of Google is under fire. Search engine Baidu has been criticised following the death of 21-year-old student Wei Zai, who used the search engine to research esoteric treatments for his cancer.